Previous 10 | Next 10 |
Astria Therapeutics, Inc. (“Astria Therapeutics,” “Astria,” the “Company,” “our,” or “us”) (Nasdaq: ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, tod...
2023-10-11 17:47:34 ET More on Astria TherapeuticS Astria Therapeutics: Too Much Baggage, Too Strong A Competition Astria wins FDA fast track tag for lead candidate Seeking Alpha’s Quant Rating on Astria TherapeuticS Historical earnings data for Astria...
-- Differentiated Preclinical Lead Candidate STAR-0310 to be Developed as a Potential Best-in-Class Long-Acting Treatment for Atopic Dermatitis – -- Conference Call and Webcast to be Held on October 12, 2023 at 8:30am ET -- Astria Therapeutics, Inc. (NASDAQ:ATXS), a b...
2023-09-19 08:00:00 ET Summary Astria Therapeutics (formerly Catabasis Pharma) has raised $100 million and acquired Quellis to develop STAR-0215, a plasma kallikrein inhibitor for hereditary angioedema (HAE). STAR-0215 has a longer half-life than existing HAE treatments, potential...
Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema (HAE) and focused on life-changing therapies for rare and niche allergic and immunological diseases, today announced that preclinical data supporting STAR-0215...
Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema (HAE) and focused on life-changing therapies for rare and niche allergic and immunological diseases, today announced that it will present information regarding pa...
2023-08-07 17:08:13 ET Astria TherapeuticS press release ( NASDAQ: ATXS ): Q2 GAAP EPS of -$0.45 beats by $0.04 . As of June 30, 2023, Astria had cash, cash equivalents and short-term investments of $203.0 million, compared to $226.4 million as of December 31, 2022. ...
-- STAR-0215 Granted Fast Track Designation by the U.S. FDA -- -- New Results from Healthy Subjects Informing STAR-0215 Administration Plan Expected in Q4 2023 -- -- ALPHA-STAR on Track with Initial Proof-of-Concept Results in Patients Anticipated Mid-2024 -- Astria Th...
Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema and focused on life-changing therapies for rare and niche allergic and immunological diseases, granted stock options to purchase 174,000 shares of Astria’s...
-- On Track for Proof-of-Concept Results in HAE Patients in Mid-2024 -- -- Results To-Date Support STAR-0215 Administration Once Every Three or Six Months for Robust Suppression of HAE Attacks -- Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing...
News, Short Squeeze, Breakout and More Instantly...
Astria Therapeutics Inc. Company Name:
ATXS Stock Symbol:
NASDAQ Market:
Astria Therapeutics Inc. Website:
2024-06-16 18:52:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced that it will present final STAR-0215 Phase 1a healthy subject data in an encore presentation at the upcoming Eastern Allerg...
Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced that it will present two posters at the upcoming European Academy of Allergy and Clinical Immunology (EAACI) Congress in Va...